The epidemic of respiratory disease in early 2010 was characterised by coughing and nasal discharge.
The disease spread through the population of 77,000 Icelandic horses within weeks, leading to a self-imposed ban on their export and significant economic cost to the country.
Initially, due to the speed at which the disease had spread, a viral cause was suspected. However, investigations by researchers at the University of Iceland showed that only Streptococcus zooepidemicus was consistently recovered from coughing horses and rare fatal cases of infection. However, this bacterium is also often found in healthy horses.
The AHT and the Wellcome Trust Sanger Institute were brought in to investigate. Dr Simon Harris from the Wellcome Trust Sanger Institute said: "To identify the culprit, we sequenced the DNA from 257 samples of bacteria from diseased animals and people. This showed that one specific strain of S. zooepidemicus, called ST209, was the likely culprit, and we also found this strain in a human case of blood poisoning. This study highlights, for the first time, how DNA sequencing can be used to identify endemic strains of bacteria and distinguish them from the cause of an epidemic infection."
Iceland is free of all major equine infectious diseases thanks to the ban on the importation of horses into the country in 1882. Consequently, Icelandic horses are particularly susceptible to any new bacteria or virus that crosses the border, and so strict biosecurity regulations are in place to help protect them.
Dr. Sigríður Björnsdóttir of the MAST Icelandic Food and Veterinary Authority, used information from owners and veterinary surgeons to build an epidemiological network. This enabled her to identify an equine rehabilitation centre where horses exercised in a water treadmill. The water treadmill is thought to have provided the perfect conditions for transmitting the disease as water was splashed up and ingested. Horses would complete their rehabilitation and return home, whilst incubating the disease, taking the infection with them.
The ST209 strain of S. zooepidemicus found in Iceland has also been recovered from a coughing horse in Sweden and an abdominal abscess in a Finnish horse trainer.
Dr Andrew Waller, Head of Bacteriology at the AHT, said: "There are a couple of theories as to how the strain entered Iceland. These bacteria are able to survive outside a horse for a week or so, which means the import of contaminated equipment or clothing is the most likely route by which ST209 entered Iceland. However, this particular strain could have even infected a human who travelled to Iceland, before spreading the strain back to a horse and triggering the epidemic.
"We are delighted to have helped uncover the likely identity of the cause of this epidemic. Our investigation highlights the ability of S. zooepidemicus strains to cause disease in animals and people. We found evidence that even endemic strains of S. zooepidemicus were likely causing cases of respiratory disease in Icelandic horses, illustrating that this group of bacteria causes more clinical problems in horses than was previously thought. We hope that raising awareness of the cause of this epidemic, and the likely involvement of a water treadmill as a key factor in disease transmission, will encourage veterinarians around the world to improve disease control precautions preventing future epidemics."
Dechra Veterinary Products has launched Myorelax, a guaifenesin 100 mg/ml solution for infusion for horses which, the company says, relaxes skeletal muscles within minutes.
Dechra's Equine Brand Manager Emma Jennings said: "Myorelax is indicated for the induction of muscle relaxation and immobilisation, as an adjunct to balanced anaesthesia.
"We're delighted to launch this product, which can be combined with a number of sedatives and anaesthetics including detomidine, ketamine and propofol plus local and volatile anaesthetics.
"Myorelax is a centrally acting muscle relaxant which is effective within a few minutes and does not affect the animal's respiratory muscles at therapeutic doses. It can be used in combination with a sedative and local anaesthetics for short procedures and together with appropriate general anaesthetics for induction and maintenance of muscle relaxation during anaesthesia."
Dechra says that horses are able to stand within 45 minutes after single administration, and the product can be used in a 'triple drip' protocol for total intravenous anaesthesia.
Myorelax is available in 500 ml bottles from veterinary wholesalers.
For further information, visit www.dechra.co.uk
Ophtocycline is licensed for the treatment of keratitis, conjunctivitis and blepharitis caused by Staphylococcus spp., Streptococcus spp., Proteus spp., and/or Pseudomonas spp.
Dechra says chlortetracycline hydrochloride works against both aerobic and anaerobic Gram-negative and Gram-positive bacteria.
The recommended dosage is four times a day for five days. The 10 mg/g ophthalmic ointment has a 14-day broached shelf life. There is a one-day withdrawal period for meat and offal.
Dechra Brand Manager Carol Morgan said: "Ophtocycline provides veterinary professionals with a targeted treatment to effectively tackle the growing and reproducing bacteria that causes these eye conditions.
"Chlortetracycline is a bacteriostatic antibiotic which interferes with bacterial protein synthesis in the rapidly growing and reproducing bacterial cell and has both time-dependent and concentration dependent effects.
"We are very pleased to be able to roll out this product to the UK market as part of our ophthalmic range alongside popular products such as Isathal."
For more information visit: www.dechra.co.uk
Zoetis, maker of Zylexis, is highlighting a new review published in Veterinary Immunology and Immunopathology, which has concluded that immune-modulators may provide a valuable contribution to the reduction of some equine respiratory diseases
The study reviewed the immune-modulators Parapoxvirus ovis and Propionbacterium acnes for the prevention of respiratory disease and other infections in the horse.
Parapoxvirus ovis (iPPVO) and Propionibacterium acnes (P.acnes) are currently used in equine medicine as immune-modulators for prophylactic treatment or adjunct to conventional therapy in order to improve immune defences, to prevent or treat infectious diseases. Their mode of action relies on a non-antigen-specific interaction with the innate and/or adaptive immune responses. iPPVO stimulates and regulates cytokine secretion by a number of leucocytes, while P. acnes acts primarily through activation of macrophages.
The review, conducted by Romain Paillot of the Animal Health Trust, Centre for Preventive Medicine, Newmarket, examined current scientific literature and reports on the use of immune-modulators in horses, particularly for the prevention or treatment of equine respiratory disease.
Stress factors such as weaning, transport and co-mingling predispose horses to infection and increase susceptibility to respiratory pathogens such as Streptococcus zoopidemicus and EHV-1/4. In the past 15 years iPPVO has been tested against several equine infectious respiratory diseases.
The review examined the results of studies on the beneficial use of iPPVO to limit the severity of respiratory infectious diseases in young horses, one of which evaluated the use of iPPVO for protection in yearlings exposed by contact challenge to EHV-1 or EHV-42,3,4. Yearlings treated with iPPVO were co-mingled with horses experimentally infected with EHV-1 and the trial was repeated with horses infected with EHV-4. Horses treated with iPPVO showed a 40% reduction in disease severity in the EHV-1 study and a 61% reduction in the EHV-4 study.
Further studies showed significantly increased frequency of recovery in horses with clinical signs of respiratory disease that had been treated with P. acnes. The decrease in disease severity was also significantly improved in the treated groups5,6.
Romain Palliot concluded: "Non-specific immune-modulators such as iPPVO or P. acnes may not provide protection against direct infection or transmission of respiratory pathogens but they seem to contribute to the reduction of the disease severity, subsequently reducing the frequency of complications and improving the rate of recovery."
References
Until now, research in equine veterinary science has focused primarily on the information needed to prevent and cure disease, with little attention paid to the attitudes and actions of horse owners, veterinary surgeons, and numerous other professionals to implementing science-based advice.
This special EVJ collection showcases studies that seek to understand horse owner behaviour around their horse’s health, supplementing clinical evidence with information about the real-life behaviours of equine owners and professionals and the factors that influence them.
It includes papers on horse owner knowledge and opinions on recognising colic, treating infectious disease, uptake of some of the most basic preventive health measures such as vaccination and deworming as well as attitudes and behaviour around equine obesity and laminitis.
Other studies highlight the importance of professionals other than vets such as farriers, equine podiatrists, physiotherapists, dental technicians, chiropractors, and equestrian organisations such as the British Horse Society.
Guest Editor Tamzin Furtado added: “As our understanding of the drivers of behaviour develops, pre-existing behaviour change models will help us to understand the barriers and enablers to uptake.
“With dissemination of this knowledge, we have a better chance of communicating effectively and implementing change that will have a positive impact on equine welfare at individual, community, and national level.”
Professor Celia Marr, Editor of the EVJ said: “This collection is both compelling and eye-opening.
"It is dangerous to assume an understanding of the motivators of horse owner behaviours and actions; these papers confirm the current lack of comprehension, providing an invaluable insight, which will ultimately help us to accelerate improvements in equine veterinary practice and, most importantly, equine welfare.”
The virtual issue can be found at https://beva.onlinelibrary.wiley.com/doi/toc/10.1001/(ISSN)2042-3306.owner-behaviours and will be free to view until 26 December 2022.
Pfizer Animal Health's Equine Herpes Virus (EHV) vaccine (Duvaxyn EHV 1,4) has been rebranded Equip EHV 1,4).
Pfizer says that EHV is carried by most horses in the UK1 and can cause respiratory disease, abortion and more rarely neurological disease. However, it is the more common sub-clinical infections that pose the most apparent issue for the competition client, with the associated loss of performance and the potential effect on the health of the whole yard.
Once infected with EHV, a horse can harbour the virus throughout its life and potentially shed the disease to other animals without showing any outward signs. According to the company, vaccinating helps to minimise the severity of the disease itself and importantly, can also help to reduce the amount of infective virus that is shed to other in-contact horses.
Equip EHV 1,4 is given as a primary course of two vaccinations, 4-6 weeks apart followed by a single dose every six months. It can also be used as an aid in the control of EHV-1 abortion - pregnant mares should be vaccinated with a single dose during each of the 5th, 7th and 9th months of pregnancy.
For further information on Pfizer's EHV campaign, to obtain literature for your practice or to book a talk for your clients contact your Pfizer Account Manager or Pfizer Animal Health, Walton Oaks, Tadworth, Surrey KT20 7NS.
Reference
1. Eddington et al. Equine Vet. J. 1994; 26 (2): 140-142.
Amy Scott MRCVS, Boehringer Ingehlheim’s performance horse portfolio manager, said: "Arti-Cell Forte is the first 'ready-to-use' stem cell-based product to be licensed in any veterinary species, and the only stem cell treatment to contain induced cells, representing a significant leap forward in both stem cell therapies and medicine as a whole.
"Arti-Cell Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage. Studies have shown that chondrogenically induced stem cells demonstrate an enhanced clinical outcome compared to un-induced stem cells in the treatment of joint disease in horses¹."
"This makes Arti-Cell Forte a highly targeted and effective treatment for cartilage damage associated with degenerative joint disease."
Arti-Cell Forte is available direct from Boehringer Ingelheim to veterinary practitioners.
It needs to be stored at ultra-low temperatures to maintain its two year shelf life from manufacture, either frozen at -70 ⁰C to -90 ⁰C (dry ice, -80 ⁰C freezer) or -196 ⁰C (liquid nitrogen) until immediately prior to injecting.
The company is providing full training on storage and administration via face-to-face CPD at practice meetings or specific CPD events*.
For more information, contact your local territory manager or ring Boehringer's Technical Services Team on 01344 746957, or email vetenquiries@boehringer-ingelheim.com
The invaluable work done by equestrian vets in the UK is to be recognised with a new award sponsored by leading equine insurance provider Petplan Equine at the Animal Health Trust Awards in November. The ‘Petplan Equine Vet of the Year' award people's vote will reflect the huge contribution made by vets to the equine community.
Owners and riders will be able to nominate their equine vet for the award if they feel that they are deserving of the recognition that this accolade would bring. Veterinary practice personnel are also encouraged to nominate a colleague who they feel has gone beyond the call of duty. Leaflets have been sent to practices across the UK outlining how to nominate and people can also register through the Petplan Equine website www.petplanequine.co.uk. A short list will be drawn up from the nominations received and an independent panel will decide the winner, who will receive his or her award at the Animal Health Trust Equestrian Awards in London on November 6th 2008.
This year marks the 20th anniversary of the Animal Health Trust Equestrian Awards, which recognise the outstanding achievements made by horses, riders, owners and trainers throughout the equestrian world. This milestone coincides with Petplan Equine's 20th anniversary and, since 1994 when the Petplan Equine Charitable Trust was founded, it has raised over £5 million, almost £500,000 of which has been donated to the AHT to fund research and development.
Jo Whitaker of Petplan Equine says: "It has been a privilege to be involved with the AHT Awards over the years and we look forward to this exciting 20th anniversary year. Petplan Equine has sponsored the Eventing Award for the past three years but this new award will recognise the commitment and hard work of people within the equine veterinary profession and the service they provide to horse owners. Horse welfare is paramount at Petplan Equine and we are committed to promoting responsible horse ownership, through our wide range of policies, our charitable contributions and our Horse Handbook. This award will give the equine community the opportunity to acknowledge and celebrate the vet who has made the most outstanding contribution to the care of horses."
To nominate go to www.petplanequine.co.uk. The closing date for nomination is 3rd October 2008.
Kruuse has announced that it has become the exclusive UK and Ireland distributor for Pulse Veterinary Technologies LLC shockwave systems, including the Versatron, Versatron 4paws and Equitron.
Shockwave therapy, otherwise known as extracorporeal shock wave therapy (ESWT), uses a high-energy sound wave that rapidly increases pressure as it travels through tissue. It is a non-invasive modality used to stimulate healing particularly in ligament, tendon or boney structures.
Andrew Groom, Managing Director, Kruuse UK Ltd said: "This agreement widens the Kruuse equine and small animal capital equipment profile within the UK and Ireland; increasing the range of technologies available to the veterinary practitioner , whilst providing aftercare support of existing shockwave users".
Eric Goorno , Chief Executive Officer, Pulse Veterinary Technologies LLC said: "This exciting partnership will further enhance our presence within the veterinary industry and allow Kruuse UK to bring leading edge technology to its customers, building upon its strong relationships within veterinary practices".
Nerfasin vet is available in two concentrations - a 100 mg/ml (10%) solution for cattle and horses and 20 mg/ml (2%) solution for cattle, horses, cats and dogs.
Nerfasin vet is on sale in 25 ml vials.
For more information visit: www.dechra.co.uk.
Horiba Medical - UK has launched MLT-Diode Laser Systems, specifically designed for veterinary use, as part of its portfolio of animal healthcare products.
According to the company, the MLT-Diode Lasers are highly versatile and can be used in a variety of veterinary applications including surgery, endoscopy, dentistry and irradiation.
The two models, the MLT-Diode Laser Classic and Premium, both feature touch screen controls and are adaptable to each users individual preferences. Designed with small animal practices in mind, the Classic has a performance out-put of 8 watts whilst the more powerful Premium model is for equine medicine with an output of 15 watts. The system is mounted on a mobile cart with a protection case, allowing the whole system to be moved between treatment rooms and enabling near patient application.
Horiba Medical will be exhibiting the MLT-Diode Laser Systems at the London Vet Show at Olympia, 22nd to 23rd October 2010, on Stand M4.
The research found that 93% of practices have a washing machine on site, but two thirds of those use a domestic machine rather than a commercial one. 69% of staff also take their uniform home to wash in a domestic machine.
Only commercial machines conform to the WRAS regulations, with thermal disinfection capabilities to minimise the risk of cross infection.
The survey also provided an argument for using a robust commercial machine able to cope with high levels of usage and the variety of materials needing to be cleaned: 83% of practices said they use their machines more than once a day and listed bedding, drapes and gowns as the most common materials that need to be cleaned regularly.
Les Marshall, Sales & Marketing Director at Miele Professional, said: "Our research shows that veterinary staff realise the importance of hygiene when cleaning their laundry. At Miele Professional we understand that preventing infection is key. When caring for animals who need medical care, reliable and effective equipment that can wash items ranging from bedding to gowns to reusable bandages is essential.
"As a leading supplier to the care and hospital sectors, all our machines are tested and approved to Water Regulatory Advisory Scheme (WRAS) category 5 for mains connection in any high-risk establishment."
The company says that in addition to meeting WRAS category 5 requirements, it's machines:
Miele Professional is exhibiting at the London Vet Show and will be holding a seminar on 'Controlling the risk of infection with a commercial laundry system' in the Business Theatre on 18 November, 12-12.50pm.
The seminar will explore the benefits of using a commercial laundry over a domestic machine, best practice around thermal disinfection and why it’s vital for veterinary practices to meet WRAS category 5 requirements.
For more information visit www.miele.co.uk.
95 respondents were surveyed online in June 2016
Ceva Animal Health has highlighted a new study which revealed that the use of the opioid buprenorphine, the active ingredient in Vetergesic, before equine elective general anaesthesia and surgery resulted in better post-operative analgesia than butorphanol, without causing further physiological disruption than is normally expected of general anaesthesia in horses.
The prospective, randomised and blinded multicentre study, conducted by Dr Polly Taylor VetMB MA PhD DVA DipECVAA MRCA MRCVS, an RCVS Specialist in Veterinary Anaesthesia, compared the degree of post-operative pain and physiological variables in horses following premedication with either buprenorphine or butorphanol in a general clinical setting. The study included 89 healthy adult horses from six UK equine veterinary clinics admitted for routine elective surgical procedures.
Ceva says that butorphanol is often used in equine procedures due to familiarity and its value for enhancing alpha2-induced sedation, but that it is probably the least effective opioid as an analgesic. There is also a common perception that butorphanol has less impact on locomotor stimulation and depression of intestinal motility than other opioids. This is likely to have contributed to the almost exclusive use of NSAIDs to manage pain in the post-operative period.
To view the full study, visit http://onlinelibrary.wiley.com/doi/10.1111/evj.12442/abstract. For details on Ceva's analgesic product range, email analgesics-group@ceva.com or call 01494 781510.
Intervet/Schering-Plough Animal Health, has launched a new guide entitled ‘Your guide to Exotic Diseases', to educate horse owners on these potentially fatal, insect-borne diseases, some of which are zoonotic.
Joining the company's guides on respiratory disease and vaccination, the leaflet features information on West Nile Virus, African Horse Sickness, Equine Infectious Anaemia (Swamp Fever) and Equine Encephalitis including overviews of each of the diseases and their clinical signs.
Spread by a variety of insect-borne vectors including midges, mosquitoes and horseflies, climate change is increasing the risk of exotic diseases having a severe impact on the country's equine industry. What's more, African Horse Sickness is transmitted from animal to animal by infected biting Culicoides midges, the same midges that carry the Bluetongue virus which has threatened UK livestock this year.
"It's essential that horse owners are aware of the threat of exotic diseases coming in from overseas and the clinical signs to look out for, especially during the summer and autumn months when diseases transmitted by insects are more likely to appear." comments Tim Zoch, Marketing Manager at Intervet/Schering-Plough Animal Health. "Our new leaflet features easy-to-understand overviews of each of the diseases to help educate owners, and practices can expect strong demand from their clients"
For further information about Intervet/Schering-Plough's range of horse owner guides, including ‘Your guide to Exotic Diseases', please contact your Intervet/Schering-Plough Account Manager or call the Veterinary Support Group on 01908 685685.
Merial Animal Health has announced that it has purchased the the anti-inflammatory treatment for lameness in horses, Hyonate® (sodium hyaluronate), from Bayer.
Merial's equine marketing and technical manager, Louise Radford MRCVS said: "Hyonate is an established treatment of lameness in horses due to non-infectious inflammation of joints, using both intra-articular (IA) and intravenous (IV) injection.
"The beneficial effects of HA supplementation are attributable to the anti-inflammatory effects, improvement in viscoelastic properties of the synovial fluid, and interaction with the synovial membrane affecting pain transmission and joint metabolism¹."
For more information telephone Customer Support on 0870 6000123 or contact your local Merial Equine Specialist.
Omics refers to a field of biological sciences including genomics (studying DNA), transcriptomics (RNA), proteomics (proteins) and metabolomics (metabolites).
Guest Editor Carrie Finno has contributed an editorial in support of the nine EVJ articles demonstrating how genomic and transcriptomic approaches have been used to investigate equine diseases.
She said: “While equine genomics and transcriptomics continue to evolve, improvements in the annotation of the equine genome will undoubtedly accelerate the rate of discovery.
"With the need for large sample sizes of well-phenotyped horses to study the most complex diseases, equine genomics and transcriptomics research will likely become increasingly collaborative, similar to the current status of human genomics initiatives.
"Aligned with this collaborative effort is the strong need for publicly available genomic and transcriptomic data that are accessible to all researchers.”
Guest Editor James Anderson prefaces five papers on advances made in equine medicine within the disciplines of proteomics, metabolomics and lipidomics (a subset of metabolomics).
He said: “Omics technologies have enhanced our knowledge of the molecular world and provided fascinating insight into the composition and functions of these components across a range of different animal species.
"Particularly for equine science and medicine they have increased our understanding of molecular changes in disease and informed the development of diagnostic tests.
"Although still in its infancy within equine veterinary science, this field looks likely to have a significant impact in the coming years.”
The virtual Issue is available to all at https://beva.onlinelibrary.wiley.com/doi/toc/10.1001/(ISSN)2042-3306.OmicsEVJ
This year's National Equine Health Survey, conducted by the Blue Cross and supported by Zoetis, has revealed that 20% of owners who claimed to have treated for encysted small redworm (ESRW) used a wormer that was not indicated to treat the parasite.
3,669 horse owners took part in the survey, which was conducted in May 2014. It contained 25 questions on general horse health, care and management and was validated by Professor Josh Slater at the Royal Veterinary College.
Zoetis says the findings suggest that horses are being left at serious risk (untreated, encysted small redworm may develop and emerge en masse from the gut wall, causing diarrhoea and colic with a mortality rate of up to 50%1).
The company is now running an encysted small redworm awareness campaign at www.esrw.co.uk, where owners can test their knowledge before discussing the best treatment options with their vet.
1. Dowdall S.M.J. et al (2002) Veterinary Parasitology 106, 225‑242
Pfizer Animal Health is reminding horse owners of the importance of treating encysted small redworm larvae this autumn.
According to the company, these hidden, dormant parasites can account for up to 90% of the redworm burden in a horse (1). Furthermore, encysted small redworm larvae won't show up in a faecal egg count (FEC). Even if a horse has shown a negative or low count it could still be harbouring several million harmful larvae, hidden within the gut wall (2)
Encysted small redworm are a potential time bomb, with the ability to survive inside a horse for up to two years. They usually 'wake-up' in the late winter or early spring, developing and emerging from the gut wall all at the same time. Such a sudden mass emergence can cause a disease syndrome known as 'larval cyathostominosis', causing diarrhoea and colic with up to a 50% mortality rate (2). Treating encysted small redworm successfully in the late autumn or early winter is vitally important in order to prevent this serious risk.
Pfizer says that Moxidectin, the key ingredient of EQUEST, is recognised as the only single dose treatment for encysted small redworm. It has been shown to kill the larvae in-situ, without resulting in severe inflammation of the gut wall that other multi-dose treatments may cause (3). In addition, Moxidectin is licensed for persistent activity against small redworm over two weeks, killing larvae ingested as the horse grazes for up to two weeks after treatment.
Ben Gaskell, Pfizer's veterinary advisor said: "A responsible and sustainable worming programme involves good pasture management, regular diagnostic tests and targeted worming, carefully planned using specialist advice. However, it is also vital to remember the danger of encysted small redworm. Even if a horse's FEC is clear, there could still be a significant encysted small redworm burden that must be treated properly every year in late autumn / early winter."
1) Bairden K. et al (2001) Veterinary Record 148, 138-141 2) Dowdall S.M.J. et al (2002) Veterinary Parasitology 106, 225‑242 3) Steinbach T. et al (2006) Veterinary Parasitology 139, 115‑131
Chanelle's head of sales and marketing, Killian Gaffney said: "The total UK market is around 80,000 bottles annually. However, with the major supplier announcing some re-stocking in March but full availability still under question, there is a real sense of urgency for practitioners.
"The Chanelle team worked throughout December with our manufacturing division to ensure that the UK product shortfall could be alleviated.
"Air freighting supplies seemed the obvious course of action, and ensured we could supply the UK market as quickly as possible."
For further information, contact: Chanelle on 00353 91 841 788.
Research published in EVE by Pearson in 2020 reported that 95% of equine vets work with “difficult” horses on at least a monthly basis, and that 81% of them had sustained at least one injury in the last 5 years.
The research also indicated that some vets overestimate their understanding of equine learning theory.
The BEVA says developing an extended understanding of how horses learn can make clinical care less stressful, and that reduced patient stress also improves workplace safety, which is important in a role that has been identified as one of the most dangerous civilian professions.
Gemma said: “Horses have limited cognitive skills and so we should try to better understand what motivates and reinforces unwanted behaviours rather than assuming the horse is being wilfully or maliciously disobedient.
“To do this we need to appreciate how horses learn.
"Better horse handling leads to happier horses, and this means happier vets and nurses and owners/clients with the ultimate knock on of better safety, better job satisfaction and better retention in the profession.”
The training sessions include:
Gemma added: “One of the biggest push backs I get from people that haven’t started to develop low stress vet care as a routine is that they haven’t got time. But those who do use it say that it saves them time and keeps them safer, this also brings obvious commercial benefit to the practice - so what’s not to like?”
https://www.beva.org.uk/elearning-redirect?redirect=/course/view.php?id=622
Equine glandular gastric disease is a complex syndrome that is distinct from gastric ulceration. A number of studies now indicate that it is an inflammatory gastritis, predominantly at the gastric outflow, which has different causes and risk factors from gastric ulcers. As such, medication effective in treating gastric ulceration may be less effective for this specific condition.
The clinical signs of EGGD are diverse and non-specific and may be mild or recurrent. They may include changes in temperament, changes in rideability, unexplained weight loss, reduced appetite or cutaneous sensitivity manifesting as biting of the flanks or resentment of girthing, grooming, leg aids or rugging. Recommendations for reducing the prevalence of disease, based on putative risk factors, include providing rest days from work, maximising turn-out, minimising management changes and other potential stress factors and minimising changes in equine companions and human carers.
The new guidelines have been published by a group of equine medicine specialists, based on a review of published and unpublished evidence. The intention is to provide veterinary practitioners with up-to-date guidance on risk factors, diagnosis, treatment, dietary management and prevention of EGGD.
David Rendle, an internal medicine specialist at Rainbow Equine Hospital in North Yorkshire who chaired the group and is a consultant editor of UK Vet: Equine said: "Our findings challenge long-standing dogma on EGGD, a condition about which there is currently very little advice available to vets and horse owners. It is becoming increasingly clear that the distinction between disease of the squamous and glandular mucosa is important clinically and the group felt that updated guidance may help to improve management of EGGD in practice."
Provision of evidence based clinical guidelines should enable practitioners to adopt more standardised and logical approaches and base EGGD management decisions on the most current data.
Professor Josh Slater, Professor of Equine Clinical Studies at the Royal Veterinary College said: "Clinical guidelines are commonly used in human health care and have been shown to improve clinical outcomes by condensing data from large numbers of research publications and promoting rapid adoption into clinical practice. These new guidelines represent a step forward in the management of this complex condition by combining a consensus of expert opinion with the best available current clinical research and evidence."
Mark Bowen, Professor of veterinary internal medicine at the University of Nottingham who is based at Oakham Veterinary Hospital said: "Whilst the panel hasn’t come up with miracle cures there was universal agreement that new treatment options have to be integrated in a logical and responsible manner."
"Our understanding of this condition is in its infancy but we hope that the summary document, which also highlights the gaps in our knowledge, will provide a useful framework for vets to follow and will be a stimulus for future research."
The guidelines can be found here: https://www.magonlinelibrary.com/doi/full/10.12968/ukve.2018.2.S1.3
Photo: Marked multi-focal depressed haemorrhagic and fibrinosuppurative lesions
The allied professionals that the BVA says should be led by veterinary surgeons include: Registered Veterinary Nurses (RVNs), Official Auxiliaries/ Meat Hygiene Inspectors, embryo transfer technicians, equine dental technicians, foot trimmers, farriers, hydrotherapists, animal behaviourists and veterinary physiotherapists.
To clarify where the responsibility for a patient sits and how it is shared between veterinary surgeons and allied professionals, the new policy statement also calls for:
The regulation of allied professionals to include mandatory veterinary diagnosis and oversight and appropriate access to veterinary records as pre-requisites before treatment;
Clarity on the delegation of duties for RVNs under Schedule 3 of the Veterinary Surgeons Act and protection of the ‘veterinary nurse’ title in legislation;
Consultation with the veterinary profession on any regulatory changes that may arise as a result of technological or other innovation.
British Veterinary Association President Simon Doherty (pictured right) said: "Against an evolving landscape, it’s essential that the veterinary profession keeps pace with change and addresses the challenges and opportunities it presents.
"Vets across sectors have always worked closely with allied professionals. The hub and spoke model acknowledges and clarifies this working relationship with clear lines of accountability and responsibility for the animals under our care. It also emphasises that vets’ right to diagnose, prescribe, and undertake surgical procedures and medical treatments must not be undermined.
"An effective and efficient vet-led team can help deliver better animal health and welfare, improved client care, and more effective use of skills within the veterinary professions. Given the ongoing workforce shortages, a strengthened veterinary workforce also has the potential to ease recruitment and retention concerns for both vets and RVNs and offer improved wellbeing.
"BVA will continue working with professional bodies and organisations to formalise the hub and spoke model, promote the value of regulation, and drive up professional standards."
According to the AHT, there is undisputed evidence that owners, riders and trainers have a poor ability to recognise signs of pain seen when horses are ridden. As a result, problems are labelled as training-related, rider-related, behavioural, or deemed 'normal' for that horse because 'that’s how he’s always gone'.
This, says the AHT, means pain-related problems are often disregarded, the horse continues in work, and the problem gets progressively worse.
Dr Sue Dyson, Head of Clinical Orthopaedics at the AHT, believes it may be easier to educate riders and trainers to recognise changes in facial expression and behaviour rather than lameness. So she and her team set out to develop and test an ethogram to describe facial expressions in ridden horses and to determine whether individuals could interpret and correctly apply the ethogram consistently.
At this stage in the project, they concluded that their ethogram could reliably be used to describe facial expressions of ridden horses by people from different professional backgrounds (full paper here: http://www.journalvetbehavior.com/article/S1558-7878(16)30184-8/fulltext).
In the next stage of the project, Sue and her team sought to demonstrate that the ethogram could be used to identify lameness.
The ethogram was applied blindly by a trained analyst to photographs (n=519) of the head and neck of lame (n=76) and non-lame (n=25) horses acquired during ridden schooling-type work at both trot and canter. These included images of seven lame horses acquired before (n=30 photographs) and after diagnostic analgesia had abolished lameness (n=22 photographs).
A pain score (0-3; 0=normal, 1-3=abnormal) was applied to each feature in the ethogram, based on published descriptions of pain in horses.
A total of 27,407 facial markers were recorded, with those giving the greatest significant difference between lame and sound horses including ears back, eyes partially or fully closed, an open mouth with exposed teeth and being severely above the bit.
Pain scores were higher for lame horses than non-lame horses (p<0.001). Total pain score (p<0.05), total head position score (p<0.01), and total ear score (p<0.01) were reduced in lame horses after abolition of lameness.
Severely ‘above the bit’, twisting the head, asymmetrical position of the bit, ear position (both ears backwards, one ear backwards and one to the side, one ear backwards and one ear forwards) and eye features (exposure of the sclera, the eye partially or completely closed, muscle tension caudal to the eye, an intense stare) were the best indicators of pain.
The researchers concluded that application of the ethogram and pain score could differentiate between lame and non-lame horses. Assessment of facial expression could potentially improve recognition of pain-related gait abnormalities in ridden horses (full paper here: http://www.journalvetbehavior.com/article/S1558-7878(17)30019-9/fulltext)
Sue and her team are now working on the development of a whole horse ethogram and its application to non-lame and lame horses, to help to differentiate between manifestations of conflict behaviour, in response to the demands of the rider, and pain. They are also working towards the development of a practical tool for recognising facial expressions, similar to that of a body condition score chart, which they say could dramatically improve the health and welfare of all horses.
Photo: Signs of pain include ears back (pain score of 3), intense stare, muscle tension and mouth. Courtesy Dr Sue Tyson.
A debate held at BEVA Congress last month ended with more than 70% of voters disagreeing with the motion: this house believes that new vet schools will benefit equine veterinary practice in the UK.
The result reflects a recent industry survey indicating that up to five times as many veterinary graduates may be seeking work in equine practice as there are jobs available.
Chris Proudman, founding head of Surrey University's new School of Veterinary Medicine and Mark Bowen, Associate Professor of Veterinary Internal Medicine at the University of Nottingham's School of Veterinary Medicine and Science, advocated that new UK vet schools are important for the advancement of the profession.
Mark Bowen said: "New UK vet schools will benefit the profession by improving the standards of veterinary education and creating what the consumer wants." He argued that new schools would help improve teaching methods and clinical training, while the resultant smaller class sizes would provide greater opportunities for hands on training. Competition would also help to drive up standards and inspire other universities to instigate much-needed changes such as focusing on quality of teaching rather than research.
Chris Proudman emphasised the flexibility of a new vet school to be progressive and innovative in both curriculum design and teaching delivery. He said: "Designing a curriculum from scratch allows novel approaches to partnership working and to the One Health agenda. New schools can deliver veterinary graduates better equipped with the skills and knowledge to be the veterinary leaders of the future."
The proposers also reasoned that if school leavers cannot find a place in a UK vet school they can now attend English language veterinary schools in universities across the EU, many of which do not have European accreditation to ensure standards of education. Therefore the increase in numbers of veterinary graduates is irresistible and the authorities can only influence the numbers trained in the UK and govern the high quality of teaching that is provided in the UK.
Alastair Welch, a partner at Donnington Grove Veterinary Group in Berkshire and Lucy Grieve, vet at Darley Pre-Training in Newmarket, staunchly countered the motion. They maintained that new vet schools would have a detrimental impact on the industry over the longer term and that their introduction demonstrated a slackening of the RCVS's management of the profession.
Alastair said: "Both anecdotal and empirical data suggest that becoming a horse vet has never been harder. The seemingly endless supply of hard-working, well-qualified school leavers determined to become equine vets provides universities with a reliable income stream for years to come but at what cost? I remain to be convinced that we will not end up educating veterinary graduates who cannot find a position in their intended career."
Lucy contended that it was irresponsible and immoral to allow individuals to commit five or six years, and tens of thousands of pounds, towards a veterinary career without them first being made aware of the limited opportunities available in very popular sectors of the profession such as equine practice.
Paul Jepson, President of BEVA, said: "With more than 70% of voters opposing the motion there is clearly a discernable level of disquiet amongst BEVA members about the current job market in equine practice and the further dilution of opportunities that increased numbers of graduates will create."
To help address the growing challenges faced by new graduates BEVA has recently introduced an Internship Awareness Programme (IAP). The scheme aims to help students and vets navigate the opportunities available as an intern and helps equine veterinary practices to find the most suitable employees for their practice.
You should be able to view the debate here: http://www.fsmevents.com/beva/congress13-session34. If not, the debate can be viewed on the BEVA website by following these instructions. Click the Webinar tab. Then click register. Then complete the £0 transaction and you will be able to access the free webinars. Select 'Free sessions' (Click the + symbol). Select 'Current Affairs: New vet schools - supply and demand?'
The company says the aim is to identify the most effective ways to minimise the risks this common and debilitating infectious equine virus poses. The survey can be found here.
Equine Herpes Virus is a contagious virus, which can cause respiratory disease, abortion and more rarely neurological disease. In addition, sub-clinical infections can be associated with a syndrome of poor performance and have a potential effect on the health of the whole yard.1
The disease is transmitted from horse to horse through the respiratory tract, by inhalation of the viral particles shed by infected horses. Once a horse is infected with Equine Herpes Virus it is likely to be latently infected for life. Viral reactivation and nasal shedding can occur at any time, particularly during stressful periods such as when mixing with other horses at equine events. This can lead to acute disease episodes. Often affected horses are asymptomatic but if they do show symptoms these may include depression, lethargy, pyrexia, nasal discharge and a dry cough. Reduction of shedding through management and vaccination is key to disease control.2
Wendy Talbot, National Equine Veterinary Manager at Zoetis said: "EHV has potentially serious health, performance and financial implications across every sector of the equestrian industry.
"The aim of our survey is to find out more about current vet protocols in practice. The results should help us to identify and then ensure that the most effective prevention strategies are accessible to vets and their clients."
The survey runs from 4 – 22nd March 2019 in parallel to a separate survey for horse owners.
For further information, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 choosing option 1.